It also said it plans to support studies to determine whether existing Pfizer medicines, including its rheumatoid arthritis drug Xeljanz, may provide benefits for those struggling with the COVID-19 respiratory illness caused by the coronavirus. More than a dozen large drugmakers, including Pfizer, have announced plans in recent months to develop vaccines and treatments for the coronavirus, although few if any are likely to reach patients in time to stem the current outbreak. Pfizer first revealed plans to try to develop an antiviral compound for COVID-19 in March, and later said it was working with BioNTech SE (22UAy. F) on a potential vaccine based on messenger RNA technology.
U.S. drugmaker Pfizer Inc said on Thursday that early data has helped it identify a drug candidate with the potential to help treat patients infected with the novel coronavirus.
Comments are closed.